Safety Profile - Jakavi
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...- Twitter Linkedin Facebook Pinterest Google plus
Reimbursement - Jakavi
Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 and for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusDose recommendation - Jakavi
Patient Resources - Jakavi
Indications - Jakavi
Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
Indication
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (APPLY-PNH)...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1 .Twitter Linkedin Facebook Pinterest Google plus